In last trading session, CytomX Therapeutics Inc (NASDAQ:CTMX) saw 0.46 million shares changing hands with its beta currently measuring 1.02. Company’s recent per share price level of $0.78 trading at -$0.04 or -4.42% at ring of the bell on the day assigns it a market valuation of $61.04M. That closing price of CTMX’s stock is at a discount of -650.0% from its 52-week high price of $5.85 and is indicating a premium of 3.85% from its 52-week low price of $0.75.

For CytomX Therapeutics Inc (CTMX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.12 in the current quarter.

CytomX Therapeutics Inc (NASDAQ:CTMX) trade information

Upright in the red during last session for losing -4.42%, in the last five days CTMX remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $0.78 price level, adding 7.54% to its value on the day. CytomX Therapeutics Inc’s shares saw a change of -24.27% in year-to-date performance and have moved -5.60% in past 5-day. CytomX Therapeutics Inc (NASDAQ:CTMX) showed a performance of -6.91% in past 30-days.

Wall Street analysts have assigned a consensus price target of 3.46 to the stock, which implies a rise of 77.49% to its current value. Analysts have been projecting 3.25 as a low price target for the stock while placing it at a high target of 3.68. It follows that stock’s current price would drop -316.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of -316.67% for stock’s current value.

CytomX Therapeutics Inc (CTMX) estimates and forecasts

This year revenue growth is estimated to rise 14.33% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 13.53M for the same. And 3 analysts are in estimates of company making revenue of 18.5M in the next quarter. Company posted 26.61M and 41.46M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 67.21% during past 5 years.

CytomX Therapeutics Inc (NASDAQ:CTMX)’s Major holders

TANG CAPITAL MANAGEMENT LLC is the top institutional holder at CTMX for having 7.79 million shares of worth $9.51 million. And as of 2024-06-30, it was holding 9.1799 of the company’s outstanding shares.

The second largest institutional holder is JANUS HENDERSON GROUP PLC, which was holding about 6.3 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4245 of outstanding shares, having a total worth of $7.72 million.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 2.46 shares of worth $1.92 million or 3.14% of the total outstanding shares. The later fund manager was in possession of 981.49 shares on Sep 30, 2024 , making its stake of worth around $0.77 million in the company or a holder of 1.25% of company’s stock.